Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia

References

• Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:1–11.
   Google Scholar
• Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–176.
   PubMed Web of Science ®Google Scholar
• Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014;4(0):266.
   PubMedGoogle Scholar
• Domino ME, Swartz MS. Who are the new users of antipsychotic medications? Psychiatr Serv. 2008;59(5):507–514.
   PubMed Web of Science ®Google Scholar
• Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand. 1996;94(2):118–124.
   PubMed Web of Science ®Google Scholar
• Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry. 2007;191:238–245.
   PubMed Web of Science ®Google Scholar
• Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol. 2000;20(2):188–194.
   PubMed Web of Science ®Google Scholar
• Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand. 1987;75(1):74–77.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Parks J, Radke A, Parker G, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull. 2009;35(5):931–936.
   PubMed Web of Science ®Google Scholar
• Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278.
   PubMed Web of Science ®Google Scholar
• Woerner MG, Correll CU, Alvir JM, et al. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology. 2011;36(8):1738–1746.
   PubMed Web of Science ®Google Scholar
• Yassa R, Lal S, Korpassy A, et al. Nicotine exposure and tardive dyskinesia. Biol Psychiatry. 1987;22(1):67–72.
   PubMedGoogle Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–425.
   PubMed Web of Science ®Google Scholar
• Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76(7):779–787.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011;100:601–616.
   PubMedGoogle Scholar
• Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872.
   PubMed Web of Science ®Google Scholar
• O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30(12):1681–1687.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–484.
   PubMed Web of Science ®Google Scholar
• Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017;78(9):1344–1350.
   PubMed Web of Science ®Google Scholar
• Marder SR, Singer C, Lindenmayer JP, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39(6):620–627.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017;88(21):2003–2010.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90(12):1317–1323.
   PubMedGoogle Scholar
• Solmi M, Pigato G, Kane JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–1238.
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Serbin M, Yonan C. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. J Comp Eff Res. 2019;8(13):1077–1088.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Final evidence report: VMAT2 inhibitors for tardive dyskinesia: effectiveness and value. Boston (MA); 2017. Available from: http://icerorg.wpengine.com/wp-content/uploads/2020/10/NECEPAC_TD_FINAL_REPORT_122217.pdf
   Google Scholar
• Lundt L, Franey E, Yonan C. Chart extraction/clinician survey shows symptom impact and favorable treatment outcomes with VMAT2 inhibitors in patients with tardive dyskinesia [meeting abstract]. Neurology. 2020;94(15 Suppl):14.
   PubMed Web of Science ®Google Scholar
• Caro JJ. Discretely integrated condition event (DICE) simulation for pharmacoeconomics. Pharmacoeconomics. 2016;34(7):665–672.
   PubMed Web of Science ®Google Scholar
• Moller J, Davis S, Stevenson M, et al. Validation of a DICE simulation against a discrete event simulation implemented entirely in code. Pharmacoeconomics. 2017;35(10):1103–1109.
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127–134.
   PubMed Web of Science ®Google Scholar
• Prater PL, Schuster AM, Lee JT, et al. Treatment in motion: analyzing the impact of valbenazine on antipsychotic persistence in a Medicare population. J Manag Care Spec Pharm. 2018;24(4-a Suppl):S7.
   Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071.
   PubMed Web of Science ®Google Scholar
• Di Capite S, Upthegrove R, Mallikarjun P. The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication. Early Interv Psychiatry. 2018;12(5):893–899.
   PubMed Web of Science ®Google Scholar
• Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry. 2007;7:40.
   PubMed Web of Science ®Google Scholar
• Panish J, Karve S, Candrilli SD, et al. Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. J Pharm Health Serv Res. 2013;4(1):29–39.
   PubMedGoogle Scholar
• Park T, Kuntz KM. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia. Value Health. 2014;17(4):310–319.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, O'Day K, Meyer K, et al. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release. J Med Econ. 2013;16(8):987–996.
   PubMedGoogle Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.
   PubMed Web of Science ®Google Scholar
• Crump C, Sundquist K, Winkleby MA, et al. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70(9):931–939.
   PubMed Web of Science ®Google Scholar
• Chiu M, Vigod S, Rahman F, et al. Mortality risk associated with psychological distress and major depression: a population-based cohort study. J Affect Disord. 2018;234:117–123.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736.
   PubMed Web of Science ®Google Scholar
• Caroff SN, Yeomans K, Lenderking WR, et al. RE-KINECT: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. J Clin Psychopharmacol. 2020;40(3):259–268.
   PubMed Web of Science ®Google Scholar
• Caroff SN, Cutler AJ, Shalhoub H, et al. Health-related quality of life in patients with possible tardive dyskinesia based on patient and clinician assessments. Presented at: the American Psychiatric Association Annual Meeting; 2019 May 18–22. San Francisco, CA.
   Google Scholar
• Arias E. United States life tables, 2008. Natl Vital Stat Rep. 2012;61(3):1–63.
   PubMedGoogle Scholar
• Chong SA, Tay JA, Subramaniam M, et al. Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol. 2009;29(1):5–8.
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692–699.
   PubMed Web of Science ®Google Scholar
• Guo JJ, Keck PE, Jr., Li H, et al. Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population. Value Health. 2008;11(3):416–423.
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU, Nierenberg AA, et al. Revisiting the Abnormal Involuntary Movement Scale: proceedings from the tardive dyskinesia assessment workshop. J Clin Psychiatry. 2018;79(3):17cs11959.
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT, Jr., et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349–356.
   PubMed Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332–342.
   PubMed Web of Science ®Google Scholar